AbbVie triumphs in Humira case
02-07-2013
Rustle / Shutterstock.com
The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, Humira, AbbVie, The Mathilda and Terence Kennedy Institute of Rheumatology Trust, patent invalidity
